Definitive Contract HHSN261201200084C

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...

<p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>

This is a $289,828.00 SBIR Phase I contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Nicolalde R&amp;D LLC, a minority-owned, self-certified small disadvantaged business. The contract is a firm fixed-price definitive contract with a completion date of November 30, 2021. The SBIR (Small Business Innovation Research) Program Phase I award indicates this contract is for early-stage research and development activities. As a...

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...

<p>This is a $198,751 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Genomic Systems, LLC. The contract is for research and development in the TAS::75 0849::TAS area and has a period of performance ending on September 30, 2011. This SBIR Phase I contract was awarded on a Firm Fixed Price basis.</p>

<p>This is a $1,999,386.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Avoneaux Medical Institute, LLC, a veteran-owned limited liability company. The contract is for the development of spatial micropurification technology under SBIR Topic 403. The contract is a definitive, firm fixed-price contract with a period of performance ending on September 18, 2024.</p>

The U.S. National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Celldex Therapeutics, Inc. in the amount of $199,398.00 on September 20, 2012. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; and has a firm fixed price pricing type. The contract has an ultimate completion date of August 23, 2013. This SBIR Phase I award supports basic research and development activities at Celldex Therapeutics, a for-profit small...